GlassScriptPhysician profile
David S Stampfer
NPI 1093799710
$9,741.68
in general payments reported to CMS, 2019-2025
52 companies · $1,790 in 2025
The $1,790 reported for 2025 was more than what 77% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $863 · 2020: $235 · 2021: $531 · 2022: $836 · 2023: $3,494 · 2024: $1,993 · 2025: $1,790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,829 · Travel and Lodging: $1,300 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $112 · Education: $36.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,829.30 |
| Travel and Lodging | $1,300.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $111.79 |
| Education | $36.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sn Holdings, LLC | $2,007.00 | 2023 | |
| Sumitomo Pharma America, INC. | $1,559.60 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $716.44 | 2021-2025 | Erleada, Akeega |
| Bayer Healthcare Pharmaceuticals INC. | $674.07 | 2019-2025 | |
| Astellas Pharma US INC | $602.98 | 2019-2025 | Xtandi, Myrbetriq |
| Dendreon Pharmaceuticals LLC | $273.54 | 2019-2024 | Provenge |
| Urovant Sciences INC | $263.89 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $230.25 | 2019-2024 | Aveed, Xiaflex |
| Teleflex LLC | $203.85 | 2022-2024 | Urolift |
| Progenics Pharmaceuticals, INC. | $201.86 | 2023-2025 | Pylarify |
| Immunitybio, INC. | $201.09 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $192.11 | 2021-2025 | Keytruda, Lynparza |
| Ferring Pharmaceuticals INC. | $187.35 | 2019-2025 | Adstiladrin |
| Tolmar, INC. | $152.20 | 2023-2024 | |
| Pfizer INC. | $142.99 | 2019-2025 |
Show all 51 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$361,837.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Stampfer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.